...
首页> 外文期刊>Journal of Clinical Microbiology >Dried-Plasma Transport Using a Novel Matrix and Collection System for Human Immunodeficiency Virus and Hepatitis C Virus Virologic Testing
【24h】

Dried-Plasma Transport Using a Novel Matrix and Collection System for Human Immunodeficiency Virus and Hepatitis C Virus Virologic Testing

机译:使用新型基质和收集系统对人免疫缺陷病毒和丙型肝炎病毒进行病毒学检测的干血浆运输

获取原文
           

摘要

A novel method for the collection and transportation of dried-blood-plasma samples, SampleTanker (ST), was developed and compared to standard shipping protocols for frozen-plasma specimens containing human immunodeficiency virus type 1 (HIV-1) and/or hepatitis C virus (HCV). Matched frozen and dried 1-ml EDTA-containing plasma samples were collected and analyzed by several molecular-based virologic assays. After addition of 1.175 ml of reconstitution buffer, 1.035 ml of dried plasma was recovered. Mean intra-assay variances were 0.05, 0.05, and 0.06 log10 copies/ml for the Versant, Amplicor, and NucliSens QT HIV-1 load assays, respectively (P, not significant). However, mean HIV-1 viral load was consistently reduced in dried samples by 0.32 to 0.51 log10 copies/ml, depending on assay type (P < 0.05). Infectious HIV-1 was not recovered from dried ST plasma. There was no significant difference in HIV-1 viral load results obtained using ST after 8 weeks of storage at ambient temperature. Compared to frozen plasma, HIV-1 genotypic results were >99% concordant at the nucleotide and amino acid levels, as well as for resistance-associated mutations. We further demonstrated successful detection of multiple analytes, including HIV-1 viral load, HIV-1 antiretroviral resistance genotype, and HCV genotype, from a single ST unit. Dried plasma collected with ST yielded comparable results to frozen samples for multiple-analyte clinical testing. As such, ST could be a useful alternative for virologic tests and clinical trials worldwide by significantly diminishing transportation cost and the sample volume restrictions associated with dried-blood-spot technology.
机译:开发了一种新的干血血浆样品收集和运输方法,SampleTanker(ST),并将其与包含人免疫缺陷病毒1型(HIV-1)和/或丙型肝炎的冷冻血浆样品的标准运输协议进行了比较病毒(HCV)。收集匹配的冷冻干燥的1 ml含EDTA的血浆样品,并通过几种基于分子的病毒学分析进行分析。加入1.175ml的重建缓冲液后,回收1.035ml的干燥血浆。对于Versant,Amplicor和NucliSens QT HIV-1负载分析,平均批内差异分别为0.05、0.05和0.06 log 10 / ml( P ,不重要)。但是,根据检测类型的不同,干样品中的平均HIV-1病毒载量始终降低0.32至0.51 log 10 拷贝/ ml( P <0.05)。没有从干燥的ST血浆中回收感染性HIV-1。在室温下保存8周后,使用ST获得的HIV-1病毒载量结果没有显着差异。与冷冻血浆相比,HIV-1基因型结果在核苷酸和氨基酸水平以及与耐药相关的突变方面的一致性> 99%。我们进一步证明了从单个ST单元成功检测到多种分析物,包括HIV-1病毒载量,HIV-1抗逆转录病毒耐药基因型和HCV基因型。用ST收集的干燥血浆产生的结果可与冷冻样品进行多分析物临床测试。因此,ST可以显着降低运输成本和与干血斑技术相关的样本量限制,从而成为全球病毒学测试和临床试验的有用替代方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号